MCM
GMAB icon

MV Capital Management’s Genmab GMAB Stock Holding History

MV Capital Management’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$993 Buy
37
+27
+270% +$809 ﹤0.01% 868
2025
Q4 		$308 Buy
+10
New +$312 ﹤0.01% 981

Other funds holding GMAB

OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
HL
Harding Loevner Bridgewater, New Jersey $9.72B AUM 22.38% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

MV Capital Management's GMAB Position: Q1 2026 in Review

MV Capital Management increased its Genmab (GMAB) stake by 270% in Q1 2026, buying an estimated $809 and bringing the position to 37 shares worth $993. The position accounts for ﹤0.01% of the portfolio, ranked #868.

MV Capital Management first reported a position in GMAB in Q4 2025 and has held it in 2 quarters since. 272 funds tracked by Wall St. Rank hold GMAB as of Q1 2026.

  • MV Capital Management held 37 shares of Genmab worth $993 as of Q1 2026.
  • MV Capital Management bought 27 Genmab shares in Q1 2026, an estimated $809.
  • Genmab made up ﹤0.01% of MV Capital Management's portfolio in Q1 2026, its #868 holding.
  • MV Capital Management first reported a position in Genmab in Q4 2025 and has held it in 2 quarters since.
  • 272 funds tracked by Wall St. Rank held Genmab as of Q1 2026.

Based on MV Capital Management's 13F filing for Q1 2026, filed 30 Apr 2026.